An oligomeric compound for use in a method of therapy, in which the oligomeric compound is delivered to the CNS, wherein the oligomeric compound comprises a modified oligonucleotide consisting of 10 to 30 linked nucleosides, wherein the modified oligonucleotide has a sugar motif comprising: a 5'-region consisting of 2-8 linked 5'-region nucleosides, each independently selected from among a modified nucleoside and an unmodified deoxynucleoside, provided that at least one 5'-region nucleoside is a modified nucleoside and wherein the 3'-most 5'-region nucleoside is a modified nucleoside; a 3'-region consisting of 2-8 linked 3'-region nucleosides, each independently selected from among a modified nucleoside and an unmodified deoxynucleoside, provided that at least one 3'-region nucleoside is a modified nucleoside and wherein the 5'-most 3'-region nucleoside is a modified nucleoside; a central region between the 5'-region and the 3'-region consisting of 5-9 linked central region nucleosides, wherein each central region nucleoside is an unmodified deoxynucleoside; wherein the oligomeric compound comprises one or more phosphodiester internucleoside linkages and one or more phosphorothioate internucleoside linkages; wherein the 5'-most internucleoside linkage and/or the 3'-most internucleoside linkage is a phosphorothioate internucleoside linkage; wherein each modified nucleoside comprises a modified sugar moiety and/or a modified nucleobase; and wherein the modified sugar moiety is a furanosyl that is not a naturally occurring sugar moiety, and either (a) comprises a 2'-substituent group selected from F, O-CH 3 and OCH 2 CH 2 OCH 3 ; or (b) comprises a bridge between the 4' and the 2' furanose ring atoms selected from 4'-(CH 2 )-O-2' (LNA), 4'-(CH 2 ) 2 -O-2' (ENA) and 4'-CH(CH 3 )-O-2' (cEt). a 5'-region consisting of 2-8 linked 5'-region nucleosides, each independently selected from among a modified nucleoside and an unmodified deoxynucleoside, provided that at least one 5'-region nucleoside is a modified nucleoside and wherein the 3'-most 5'-region nucleoside is a modified nucleoside; a 3'-region consisting of 2-8 linked 3'-region nucleosides, each independently selected from among a modified nucleoside and an unmodified deoxynucleoside, provided that at least one 3'-region nucleoside is a modified nucleoside and wherein the 5'-most 3'-region nucleoside is a modified nucleoside; a central region between the 5'-region and the 3'-region consisting of 5-9 linked central region nucleosides, wherein each central region nucleoside is an unmodified deoxynucleoside; wherein the oligomeric compound comprises one or more phosphodiester internucleoside linkages and one or more phosphorothioate internucleoside linkages; wherein the 5'-most internucleoside linkage and/or the 3'-most internucleoside linkage is a phosphorothioate internucleoside linkage; wherein each modified nucleoside comprises a modified sugar moiety and/or a modified nucleobase; and wherein the modified sugar moiety is a furanosyl that is not a naturally occurring sugar moiety, and either (a) comprises a 2'-substituent group selected from F, O-CH 3 and OCH 2 CH 2 OCH 3 ; or (b) comprises a bridge between the 4' and the 2' furanose ring atoms selected from 4'-(CH 2 )-O-2' (LNA), 4'-(CH 2 ) 2 -O-2' (ENA) and 4'-CH(CH 3 )-O-2' (cEt). <EOS>